Biocompatibles UK, a medical technology company involved in drug device combination products, has won an award for the development of an innovative cancer product.
The Farnham, Surrey based firm received the Institute of Materials, Minerals and Mining (IOM3) award for Polymers in the Service of Mankind for its DC Bead technology from HRH The Prince Philip, in a ceremony at Buckingham Palace.
DC Bead is a polymer-based engineering solution that ultimately deprives cancer of the nutrients and oxygen that enable it to spread. It is used in a procedure called Transarterial Chemoembolisation (TACE), a minimally invasive medical procedure to restrict a tumour's blood supply. TACE has been used extensively to delay the progression of hepatocellular carcinoma (HCC), a type of liver cancer.
Biocompatibles UK’s main aim is to deliver products that are safe to use, economically viable, with clear clinical advantages. The firm's products use specialised polymer technology engineered to allow ease of delivery to blood vessels of tumours combined with controlled drug delivery capability. It is a pioneer in the use of drug-eluting beads to treat cancer.
Biocompatibles UK Ltd has been part of BTG International group company since 2008.
The Prince Philip award was established in 1973 and is awarded biennually (subject to sufficient merit).
Biocompatibles wins IOM3 award for DC Bead technology
Polymer-based engineering solution deprives cancer cells of nutrients they need to survive
You may also like
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Neuland Laboratories announces new $20m process development lab in Hyderabad]()
Neuland Laboratories announces new $20m process development lab in Hyderabad
The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Regulatory
![FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs]()
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs
GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually
Pharmaceutical
![Maximising product recovery with a GFD filter dryer removable basket]()
Maximising product recovery with a GFD filter dryer removable basket
Product value is often inversely proportional to volume in pharmaceutical R&D and kilo-lab production. When synthesising a few hundred grams of a novel drug candidate, every milligram can represent weeks of experimentation, costly reagents, and the potential success of a clinical trial
Pharmaceutical
![How pressure and vacuum filtration in ANFDs improves yield]()
How pressure and vacuum filtration in ANFDs improves yield
During solid-liquid separation in industries such as pharmaceuticals and fine chemicals, both process efficiency and product quality are critical requirements. Effective use of pressure and vacuum filtration can help address this in downstream processing